Notice: This company has been marked as potentially delisted and may not be actively trading. Intensity Therapeutics, Inc. Common stock (INTS) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestTrends Get the Latest News and Ratings for INTS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Intensity Therapeutics, Inc. Common stock and its competitors. Enter your email to sign up for newsletter Sign Up INTS Analyst Ratings Over TimeTypeCurrent Forecast12/23/23 to 12/22/241 Month Ago11/23/23 to 11/22/243 Months Ago9/24/23 to 9/23/241 Year Ago12/23/22 to 12/23/23Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy2 Buy rating(s)2 Buy rating(s)1 Buy rating(s)1 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$8.50$8.50$12.00$12.00Forecasted Upside352.13% Upside226.92% Upside200.00% Upside94.49% UpsideConsensus RatingBuyBuyStrong BuyBuy Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem INTS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History INTS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Intensity Therapeutics, Inc. Common stock Stock vs. The CompetitionTypeIntensity Therapeutics, Inc. Common stockMedical CompaniesS&P 500Consensus Rating Score 3.33 2.81 2.51Consensus RatingBuyModerate BuyModerate BuyPredicted Upside352.13% Upside25,827.32% Upside14.53% UpsideNews Sentiment RatingVery Positive NewsSee Recent INTS NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails11/21/2024HC Wainwright2 of 5 starsS. RamakanthSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00+69.49%9/20/2024Brookline Capital Management2 of 5 starsK. RajaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/11/2024Benchmark2 of 5 starsR. WassermanSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$12.00 ➝ $12.00+144.90%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:32 AM ET. INTS Forecast - Frequently Asked Questions What is Intensity Therapeutics, Inc. Common stock's forecast for 2025? According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Intensity Therapeutics, Inc. Common stock is $8.50, with a high forecast of $12.00 and a low forecast of $5.00. Should I buy or sell Intensity Therapeutics, Inc. Common stock stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intensity Therapeutics, Inc. Common stock in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INTS shares. Does Intensity Therapeutics, Inc. Common stock's stock price have much upside? According to analysts, Intensity Therapeutics, Inc. Common stock's stock has a predicted upside of 352.13% based on their 12-month stock forecasts. What analysts cover Intensity Therapeutics, Inc. Common stock? Intensity Therapeutics, Inc. Common stock has been rated by research analysts at HC Wainwright in the past 90 days. Do Wall Street analysts like Intensity Therapeutics, Inc. Common stock more than its competitors? Analysts like Intensity Therapeutics, Inc. Common stock more than other "medical" companies. The consensus rating for Intensity Therapeutics, Inc. Common stock is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how INTS compares to other companies. Stock Forecasts and Research Tools Related Companies X4 Pharmaceuticals Stock Forecast INmune Bio Stock Forecast Adverum Biotechnologies Stock Forecast Cardiol Therapeutics Stock Forecast Century Therapeutics Stock Forecast Genenta Science Stock Forecast HilleVax Stock Forecast Scilex Stock Forecast Cellectis Stock Forecast Quince Therapeutics Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. This page (NASDAQ:INTS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics, Inc. Common stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics, Inc. Common stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
